Properties of activated microglia and pharmacologic interference by propentofylline

Alzheimer Disease and Associated Disorders

Volumn 12, Issue SUPPL. 2, 1998, Pages

  McRae, Amanda ^a   Ling, Eng Ang ^b   Schubert, Peter ^c   Rudolphi, Karl ^d  

^a UNIVERSITY OF THE WEST INDIES   (Trinidad and Tobago)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c MAX PLANCK INSTITUTE OF NEUROBIOLOGY   (Germany)

^d SANOFI   (France)

Author keywords

Amyloid; Astroglia; Dementing disorders; Microglia; Neuroprotection

Indexed keywords

AMYLOID PRECURSOR PROTEIN; ANTIBODY; MONOCLONAL ANTIBODY; NEUROTOXIN; PROPENTOFYLLINE; REACTIVE OXYGEN METABOLITE; XANTHINE DERIVATIVE;

AGE; ALZHEIMER DISEASE; AMOEBA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN RECOGNITION; BRAIN DEVELOPMENT; BRAIN ISCHEMIA; CELL PROLIFERATION; CELL STRUCTURE; CELL TRANSFORMATION; CEREBROSPINAL FLUID; CONFERENCE PAPER; CONTROLLED STUDY; FOREBRAIN; GERBIL; IMMUNOCYTOCHEMISTRY; IMMUNOPHENOTYPING; INTRAPERITONEAL DRUG ADMINISTRATION; MACROPHAGE; MICROGLIA; NERVE CELL LESION; NERVE CELL NECROSIS; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION;

ADULT; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANIMALS, NEWBORN; BRAIN ISCHEMIA; CHOLINERGIC FIBERS; DISEASE MODELS, ANIMAL; GERBILLINAE; HUMANS; MACROPHAGE ACTIVATION; MICROGLIA; NEUROPROTECTIVE AGENTS; PROSENCEPHALON; RATS; XANTHINES;

EID: 0032458796     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (34)

1. Banati R, Schubert P, Rothe G, et al. Modulation of intracellular formation of reactive oxygen intermediates in peritoneal macrophages and microglia/brain macrophages by propentofylline. J Cereb Blood Flow Metab 1994;14:145-9.
2. Boynton AL, Whitfield JF. The role of cyclic AMP in cell proliferation: a critical assessment of the evidence. Adv Cyclic Nucleotide Res 1983;15:195-294.
3. Cronstein BN, Rosenstein ED, Kramer SB, Weissmann G, Hirschhorn R. Adenosine; a physiologic modulator of superoxide anion generation by human neutrophils. J Immunol 1985;135:1366-71.
4. DeLeo J, Toth L, Schubert P, Rudolphi K, Kreutzberg GW. Ischemia-induced neuronal cell death, calcium accumulation, and glial response in the hippocampus of the Mongolian gerbil and protection by propentofylline (HWA 285). J Cereb Blood Flow Metab 1987; 7:745-51.
5. Fuji K, Masayuki H, Kameyama T, Nabeshima T. Effects of repeated administration of propentofylline on memory impairment produced by basal forebrain lesion in rats. Eur J Pharmacol 1993;236:411-7.
6. Giulian D. Reactive glia as rivals in regulating neuronal survival. Glia 1993;7:102-10.
7. Griffin WS, Stanley L, Ling C, et al. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci USA 1989;86:7611-5.
8. Kalaria RN, Bhatti SU, Palatinsky EA, et al. Accumulation of the beta amyloid precursor protein at sites of ischemic injury in rat brain. Neuroreport 1993;4:211-4.
9. Ling EA, Kaur C, Yick TP, Wong WC. Immunocytochemical localization of CR3 complement receptors with OX 42 in ameboid microglia in postnatal rats. Anat Embryol 1990;182:481-6.
10. McGeer PL, Akiyama H, Itagaki S, McGeer EG. Immune system response in Alzheimer's disease. Can J Neurol Sci 1989;16:516-27.
11. McRae A, Dahlström A, Polinsky R, Ling EA. Cerebrospinal fluid antibodies: potential diagnostic markers for immune responses in Alzheimer's disease. Behav Brain Res 1993;57:225-34.
12. McRae A, Ling EA, Polinsky R, Gottfries C, Dahlström A. Antibodies in the cerebrospinal fluid of some Alzheimer's disease patients recognize ameboid microglial cells in the developing rat central nervous system. Neuroscience 1991;41:739-52.
13. McRae A, Rudolphi KA, Schubert P. Propentofylline depresses amyloid and Alzheimer's CSF microglial antigens after ischemia. Neuroreport 1994;5:1193-6.
14. McRae A, Schubert P, Ogata T, et al. Postischemic glial responses and amyloid accumulation are modified by propentofylline: neuroprotective pharmacon for Alzheimer's disease? In: Iqbal K, Winblad B, Nishimura T, Takeda M, Wisniewski HM, eds. Alzheimer's disease: biology, diagnosis and therapeutics. New York: John Wiley, 1997:759-67.
15. Park CK, Rudolphi KA. Antiischemic effects of propentofylline (HWA 285) against focal cerebral infarction in rats. Neurosci Lett 1994; 178:235-8.
16. Parkinson FE, Fredholm B. Effects of propentofylline on adenosine A1 and A2 receptors and nitrobenzylthioinosinesensitive nucleotide transporters: quantitative and autoradiographic analysis. Eur J Pharmacol 1991;202:361-6.
17. Pike CJ, Walenceiwicz AJ, Glabe CG, Cotman CW. In vitro aging of beta amyloid protein causes peptide aggregation and neurotoxicity Brain Res 1991;563:311-4.
18. Robison PM, Clemens JA, Smalstig EB, Stephenson D, May PC. Decrease in amyloid precursor protein precedes hippocampal degeneration in rat brain following transient global ischemia. Brain Res 1993;608:334-7.
19. Rogers J, Luber-Narod J, Styren S, Civin H. Expression of immune system-associated antigens by cells of the human central nervous system: relationship to the pathology of Alzheimer's disease. Neurobiol Aging 1988;9:339-49.
20. Saido TC, Yokota M, Maruyama K, et al. Spatial resolution of the primary beta amyloidogenic process induced in postischemic hippocampus. J Biol Chem 1994;269:15253-7.
21. Schubert P, Banati R, Dux E, Gehrmann J, Rudolphi K, Kreutzberg GW. Reactive oxygen intermediates in microglial cells differentiating into brain macrophages: depression by propentofylline and relation to adenosine. In: Krieglstein J, Oberpichler H, eds. Pharmacology of cerebral ischemia. Stuttgart: Wiss Verlag 1992-461-7.
22. Schubert P, Ogata T, Ferroni S, McRae A, Nakamura Y, Rudolphi K. Modulation of glial cell signaling by adenosine and pharmacologic reinforcement. A neuroprotective strategy? Mol Chem Neuropathol 1996;28:185-90.
23. Schubert P, Rudolphi K, Fredholm B, Nakamura Y. Modulation of nerve and glial cell function by adenosine: role in the development of ischemic brain damage. Int J Biochem 1994;26:1227-36.
24. Selkoe DJ. The molecular pathology of Alzheimer's disease. Neuron 1991;6:487-98.
25. Sheng JG, Ito K, Skinner RD, et al. In vivo and in vitro evidence supporting a role for the inflammatory cytokine interleukin-1 as a driving force for Alzheimer pathogenesis. Neurobiol Aging 1996; 17:761-6.
26. Sheng JG, Mrak RE, Griffin WS. Neuritic plaque evolution in Alzheimer's disease is accompanied by transition of activated microglia from primed to enlarged to phagocytic forms. Acta Neuropathol (Berl) 1997;94:1-5.
27. Shinoda I, Furukawa Y, Furukawa S. Stimulation of nerve growth factor synthesis/secretion by propentofylline in cultured mouse astroglial cells. Biochem Pharmacol 1990;39:1813-6.
28. Si Q, Nakamura Y, Schubert P, Rudolphi K, Kataoka K. Adenosine and propentofylline inhibit the proliferation of cultured microglial cells. Exp Neurol 1996;137:345-9.
29. Stefanovich V. Effect of propentofylline on cerebral metabolism of rats. Drug Dev Res 1985;6:327-38.
30. Stephenson DT, Rash K, Clemens JA. Amyloid precursor protein accumulates in regions of neurodegeneration following focal cerebral ischemia in the rat. Brain Res 1992;593:128-35.
31. Streit WJ, Graeber MB, Kreutzberg GW. Functional plasticity of microglia: a review. Glia 1988;1:301-7.
32. Tanaka H, Araki M, Masuzawa T. Reaction of astrocytes in the gerbil hippocampus following transient ischemia: immunocytochemical observations with antibodies against glial fibrillary acid protein, glutamine synthetase and S-100 protein. Exp Neurol 1992;116: 264-74.
33. Wakita H, Tomimoto H, Akiguchi I, Ohnishi K, Nakamura S, Kimura J. Regional accumulation of amyloid beta/A4 protein precursor in the gerbil brain following transient cerebral ischemia. Neurosci Lett 1992;146:135-8.
34. Wu YP, Ling EA. Induction of microglial and astrocytic response in the adult rat lumbar spinal cord following middle cerebral artery occlusion. Exp Brain Res 1998;118:235-42.